IL1B and Alzheimer disease: A panel combining IL-1β, TNF-α, and IL-6 achieved a significantly higher AUC of 0.894, with 77.42% sensitivity and 86.00% specificity.<h4>Conclusion</h4>Elevated levels of IL-6, IL-1β, and TNF-α are strongly associated with cognitive decline in early-stage AD, suggesting their utility as potential biomarkers for disease progression.